Search

Orforglipron

Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. … [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations.

Pancrelipase amylase

Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. … [L2509] The amylases are enzymes that help in the chemical process of digestion by hydrolizing starch into more available saccharide forms.

Ocaperidone

Inavolisib

[L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605] … _PIK3CA_ is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation.

Propafenone

An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.

Digitoxin

A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting.

Fosdenopterin

[A230088] MoCD is incurable and median survival in untreated patients is approximately 36 months[A230088] - treatment, then, is focused on improving survival and maintaining neurological function. … [L43075] In September 2022, the EMA approved the use of fosdenopterin.[L43372,L43433]

Prednisone

[A187463] It is biologically inert and converted to [prednisolone] in the liver.[L10502] Prednisone was granted FDA approval on 21 February 1955.[L10496]

Rilzabrutinib

Rilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies. … [L53743] ITP is an autoimmune disorder characterized by low platelet count.

Tiotropium

Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. … [A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium].